Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).

ABSTRACT: Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis.

SUBMITTER: Birnie D 

PROVIDER: S-EPMC7367280 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature